Alkylating histone deacetylase inhibitors may have therapeutic value in experimental myeloperoxidase-ANCA vasculitis.

MLA

Dooley, Dearbhaile, et al. “Alkylating Histone Deacetylase Inhibitors May Have Therapeutic Value in Experimental Myeloperoxidase-ANCA Vasculitis.” Kidney International, vol. 94, no. 5, Nov. 2018, pp. 926–36. EBSCOhost, https://doi.org/10.1016/j.kint.2018.05.028.

APA

Dooley, D., van Timmeren, M. M., O’Reilly, V. P., Brady, G., O’Brien, E. C., Fazekas, B., Hickey, F. B., Leacy, E., Pusey, C. D., Tam, F. W. K., Mehrling, T., Heeringa, P., & Little, M. A. (2018). Alkylating histone deacetylase inhibitors may have therapeutic value in experimental myeloperoxidase-ANCA vasculitis. Kidney International, 94(5), 926–936. https://doi.org/10.1016/j.kint.2018.05.028

Chicago

Dooley, Dearbhaile, Mirjan M van Timmeren, Vincent P O’Reilly, Gareth Brady, Eóin C O’Brien, Barbara Fazekas, Fionnuala B Hickey, et al. 2018. “Alkylating Histone Deacetylase Inhibitors May Have Therapeutic Value in Experimental Myeloperoxidase-ANCA Vasculitis.” Kidney International 94 (5): 926–36. doi:10.1016/j.kint.2018.05.028.